Lonza Group will sell its Capsules & Health Ingredients division to global private equity firm Lone Star Funds, in a deal valued at 2.3 billion Swiss francs ($3 billion).
As part of the transaction, Lonza will receive upfront proceeds of ~$2.2 billion and will retain a 40% equity position in the business.
Lonza’s intent to shed its Capsules & Health Ingredients business was first shared in December 2024, when the company unveiled a new organizational structure and strategy focused on its core CDMO business. The organizational structure for the CDMO business will evolve from three divisions with nine underlying business units, to a simplified ‘One Lonza’ set-up with three integrated business platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Integrated Biologics will include mammalian and drug product services; Advanced Synthesis will comprise the former small molecules division and bioconjugates; and Specialized Modalities will include cell and gene technologies, mRNA, microbial and bioscience.
The transaction is expected to close in the second half of 2026.